VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | ctDNA vs. pathological markers

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the use of circulating tumor DNA (ctDNA) in clinical practice, which will be used alongside traditional pathological markers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter